JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $26

Benzinga · 10/03/2025 12:21
JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $23 to $26.